Phase 4 Cystic Fibrosis Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You are 6 years of age or older (any gender)
- You have been formally diagnosed with cystic fibrosis (CF)
- Your doctor plans to treat your current CF lung flare-up with a 14-day course of antibiotics given through a vein (IV)
- You have had at least one positive test result for a bacteria called Pseudomonas aeruginosa within the past two years
Who may not be able to join:
- You are currently pregnant
- You have known kidney problems or have previously received a transplanted organ (such as a kidney, liver, or lung)
- You have received IV antibiotics, been admitted to an intensive care unit (ICU), or experienced a collapsed lung or significant coughing up of blood within the past 6 weeks
- You have used an experimental treatment, started a new type of CF medication (called a CFTR modulator), or received treatment for a specific type of lung infection (called NTM) within the past 4 weeks
- You have a history of bad reactions, balance or hearing problems caused by a type of antibiotic called aminoglycosides (confirm with trial site)
- You have already received more than one day of IV aminoglycoside antibiotics for your current CF flare-up before joining the trial
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Patrick Flume, MD, Medical University of South Carolina
Phone: 206-884-7517
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Absolute Change in FEV1 % Predicted at Week 4 in Aminoglycoside (AG) Study; Incidence of Adverse Events (AEs) in Aminoglycoside (AG) Study Intervention Arms
Can't join this trial?
Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.